NASDAQ:DRMA Dermata Therapeutics Q2 2025 Earnings Report $1.10 -0.01 (-0.45%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.13 +0.02 (+2.17%) As of 10/2/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dermata Therapeutics EPS ResultsActual EPS-$1.66Consensus EPS -$2.90Beat/MissBeat by +$1.24One Year Ago EPSN/ADermata Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADermata Therapeutics Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time8:00AM ETUpcoming EarningsDermata Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dermata Therapeutics Earnings HeadlinesDermata Therapeutics announces $3.4M private placementAugust 17, 2026 | msn.comDRMA Share News TodayAugust 7, 2026 | uk.investing.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)Dermata Therapeutics Inc Share Price (DRMA.US)August 7, 2026 | lse.co.ukDermata Therapeutics Insider Trading Activity | NASDAQ:DRMA | BenzingaApril 12, 2026 | benzinga.comDermata Therapeutics (DRMA) price target decreased by 60.00% to 4.08April 9, 2026 | msn.comSee More Dermata Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dermata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your email. Email Address About Dermata TherapeuticsDermata Therapeutics (NASDAQ:DRMA) is a clinical-stage biopharmaceutical company focused on developing treatments for dermatological diseases and conditions. The company’s research is centered on topical therapies designed to address unmet needs in areas such as acne, psoriasis and other inflammatory or medical skin disorders. Dermata’s lead product candidate, DMT310, is a topical treatment platform being investigated for conditions including acne vulgaris and plaque psoriasis. The company has also developed additional topical product candidates, including DMT410, which has been studied for dermatological conditions involving excessive sweating. Its approach is intended to support localized treatment and potentially improve the delivery of active ingredients to the skin. Founded in 2014 and headquartered in San Diego, California, Dermata has conducted its development activities primarily in the United States. The company has advanced its candidates through clinical development and has worked with dermatology-focused research and commercial partners. Gerald Proeber has served as the company’s president and chief executive officer.View Dermata Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
